DearnaleyD.P., SydesM.R., MasonM.D.A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).J Natl Cancer Inst2003; 95: 1300–1311.
2.
SmallE.J., SmithM.R., SeamanJ.J.Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.J Clin Oncol2003; 21: 4277–4284.
3.
SaadF., GleasonD.M., MurrayR.Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.J Natl Cancer Inst2004; 96: 879–882.
4.
MajorP.P., CookR.J., ChenB.L.Survival-adjusted cumulative event analysis of skeletal-related events in patients with cancer metastatic to bone in trials of zoledronic acid. Presented at: What is new in bisphosphonates? Seventh workshop on bisphosphonates - from the laboratory to the patient, March 24-26, 2004, Davos, Switzerland.
5.
RosenL.S., GordonD., TchekmedyianN.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial.Cancer2004; 100: 2613–2621.
6.
LiptonA., ZhengM., SeamanJ.Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal carcinoma.Cancer2004; 98: 962–969.
7.
HillnerB.E., IngleJ.N., ChlebowskiR.T.American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.J Clin Oncol2003; 21: 4042–4057. Erratum in: J Clin Oncol 2004; 22: 1351.
8.
ColemanR.Developing more rational use of bisphosphonates. Vth International Conference on cancer-induced bone disease. Davos 20-24 March 2005.Cancer Treat Rev2005; 31(suppl. 1): S19.
9.
ConteP., GuarneriV.Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.Oncologist2004; 9(suppl 4): 28–37. Review.
10.
MiglioratiC.A.Bisphosphonates and oral cavity avascular bone necrosis.J Clin Oncol2003; 214253–4254.
11.
GreenbergMS.Intravenous bisphosphonates and osteonecrosis.Oral Surg Oral Med Oral Pathol Oral Radiol Endod2004; 98: 259–260.
12.
DurieBG.Aredia/Zometa and osteonecrosis of the jaws.International Myeloma Foundation.2004.
13.
RuggieroS.L., MehrotraB., RosenbergT.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.J Oral Maxillofac Surg2004; 62(5): 527–534.
14.
TheriaultRL.Pathophysiology and implications of cancer treatment-induced bone loss.Oncology (Williston Park)2004; 18(5 Suppl 3): 11–15. Review.
15.
SmithM.R., EasthamJ., GleasonD.M.Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non metastatic prostate cancer.J Urol2003; 169: 2008–2012.
16.
GnantM., JakeszR., MlineritshB.Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - Bone density subprotocol results of a randomized multicenter trial (ABCSG-12). San Antonio Breast Cancer Symposium 2004; abst 6.
17.
US Preventive Services Task Force.Screening for osteoporosis in postmenopausal women: recommendations and rationale.Ann Intern Med2002; 37: 26–528.
18.
HillnerB.E., IngleJ.N., ChlebowskiR.T.American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.J Clin Oncol2003; 1: 4042–4057. Erratum in: J Clin Oncol 2004; 22: 1351.
19.
BrufskyA., HarkerW., BeckJ.Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial.Proc Am Soc Clin Oncol2005; abst 533.
